암/종양 프로파일링 시장 : 바이오마커 유형별(유전자, 단백질) 기술별(NGS, PCR, ISH, IHC) 암 유형별(유방암, 폐암, 대장암, 전립선암, 백혈병) 응용 분야별(임상, 연구) 최종사용자별(제약, 학계, CRO) - -
암/종양 프로파일링 시장 2030년까지 세계 예측
세계 암/종양 프로파일링 시장은 2023년부터 2030년까지 CAGR 20.9%로 2030년까지 223억 달러에 달할 것으로 예상됩니다.
광범위한 2차 및 1차 조사, 시장 시나리오에 대한 심층 분석을 통해 이 보고서는 주요 산업 촉진요인, 억제요인, 도전 과제 및 기회 분석으로 구성되어 있습니다. 암/종양 프로파일링 시장의 성장은 암 유병률 증가, 의약품 R&D 비용 증가, 표적 치료법 증가 및 새로운 실용적인 바이오마커 발견, 암 연구에 대한 투자 증가, NGS 기반 프로파일링 비용 감소, 다중유전체 종양 프로파일링의 발전으로 인한 것입니다. 에 기인합니다. 그러나 NGS 설치에 필요한 고가의 설비 투자와 긴 처리 시간이 이 시장의 성장을 억제하고 있습니다.
또한, 맞춤형 의약품 개발에 대한 관심이 높아지고 표적치료에 대한 인식과 채택이 증가함에 따라 시장 성장의 기회가 창출될 것으로 예상됩니다. 그러나 결과를 해석할 수 있는 유전자 전문가가 부족하고, 사내에서 종양 프로파일링 기술을 사용할 수 없으며, 바이오마커의 오탐이 많다는 점은 암/종양 프로파일링 시장의 이해관계자들에게 큰 도전이 될 것으로 보입니다.
Cancer/Tumor Profiling Market by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH, IHC) Cancer Type (Breast, Lung, Colorectal, Prostate, Leukemia) Application (Clinical, Research) End User (Pharma, Academic, CRO)-Global Forecast to 2030
The global cancer/tumor profiling market is projected to reach $22.3 billion by 2030, at a CAGR of 20.9% from 2023 to 2030.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the cancer/tumor profiling market is attributed to the increasing prevalence of cancer, the rising pharmaceutical R&D expenditures, the growing number of targeted therapies and the discovery of new actionable biomarkers, increasing investments in cancer research, the declining costs of NGS-based profiling, and advancements in multi-omics tumor profiling. However, the high capital investments required for NGS setups and long turnaround times restrain the growth of this market.
Additionally, the increasing focus on developing personalized medicines and the rising awareness and adoption of targeted therapies are expected to generate market growth opportunities. However, the lack of genetic experts for interpreting results, the non-availability of in-house tumor profiling technologies, and the high number of false biomarker discoveries are major challenges for the stakeholders in the cancer/tumor profiling market.
Based on biomarker type, in 2023, the genetic biomarkers segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the effectiveness of genetic biomarkers as targets for therapeutic treatments, their role in enhancing treatment delivery, and their utility in facilitating convenient disease diagnosis.
Based on technology, in 2023, the next-generation sequencing (NGS) segment is expected to account for the largest share of the market. The large market share of the segment is attributed to the growing adoption of NGS in cancer/tumor profiling, its ability to provide faster and more accurate genetic testing, the rapidly declining cost of sequencing per base, and the introduction of cost-effective benchtop laboratory sequencers.
Based on cancer type, the cancer/tumor profiling market is segmented into breast cancer, colorectal cancer, lung cancer, prostate cancer, lymphoma, leukemia, cervical cancer, and other cancer types. In 2023, the breast cancer segment is expected to account for the largest share of the cancer/tumor profiling market. The increase in breast cancer cases, government initiatives promoting breast cancer treatment, increasing healthcare expenditure, and reimbursement for certain profiling technologies such as NGS have propelled the demand for cancer/tumor profiling for breast cancer.
Based on application, the research applications segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the rising incidence of cancer, the growing demand for precision medicine, the increased discovery of biomarkers, and the availability of cost-effective advanced profiling technologies like NGS and PCR for research applications.
Based on end user, in 2023, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the declining costs of sequencing, the development of companion diagnostics and precision medicine, and the high demand for cancer/tumor profiling from pharmaceutical and biopharmaceutical companies, primarily for biomarker discovery purposes.
An in-depth analysis of the geographical scenario of the global cancer/tumor profiling market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the cancer/tumor profiling market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's significant market share can be attributed to factors such as the rising burden of cancer, the presence of key market players, well-established healthcare infrastructure, and government initiatives aimed at bolstering cancer research efforts.
The key players operating in the global cancer/tumor profiling market are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).
Cancer/Tumor Profiling Market Assessment-by Biomarker Type
Cancer/Tumor Profiling Market Assessment-by Technology
Note: Other technologies include immunoassays, microarrays, mass spectrometers, Sanger sequencing, pyrosequencing, and fragment analysis
Cancer/Tumor Profiling Market Assessment-by Application
Cancer/Tumor Profiling Market Assessment-by Cancer Type
Note: Other cancer types include bladder cancer, melanoma, kidney cancer, stomach cancer, ovarian cancer, thyroid cancer, and head & neck cancers
Cancer/Tumor Profiling Market Assessment-by End User
Cancer/Tumor Profiling Market Assessment-by Geography